K-numberK250098
Device nameBard Soft Mesh; Bard Soft Mesh Pre-Shaped
ApplicantDavol, Inc.
Product codeFTL
Device classClass II
Decision dateApr 9, 2025
DecisionSubstantially Equivalent
Regulation878.3300
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

Bard Soft Mesh is a nonabsorbable, sterile surgical mesh made of knitted polypropylene monofilaments used to reinforce soft tissue deficiencies in adults. Bard Soft Mesh is indicated for repair of ventral, incisional, and inguinal hernias, while the Pre-Shaped variant is specifically indicated for inguinal hernia repair. The mesh comes in various rectangular and pre-shaped sizes ranging from 2"×4" to 12"×12".

Technological characteristics

The subject device is identical to the predicate device in design (single-layer knitted polypropylene monofilaments), materials, manufacturing, packaging, sterilization method (ethylene oxide), biocompatibility, and shelf-life. The subject device adds a 12"×12" size option and clarifies indications to specify ventral, incisional, and inguinal hernias rather than broad hernia repair language, but these are labeling modifications only with no physical device changes.

Test standards cited

The submission references the FDA Guidance for the Preparation of a Premarket Notification Application for a Surgical Mesh issued March 2, 1999. Non-clinical testing included mesh thickness, knit construction, pore size, density, tensile strength, stiffness, ball burst strength, tear resistance, and suture pull-out testing.

Substantial equivalence argument

The subject and predicate devices are substantially equivalent because the subject device has identical intended use (soft tissue reinforcement for hernia repair), identical technological characteristics (same material, design, and manufacturing), and identical principles of operation. The differences are labeling clarifications and a size extension (12"×12"), which do not constitute new risks or new intended uses since both devices are indicated for the same tissue type and disease entity. Risk analysis determined the labeling changes result in no new or increased risks, and non-clinical testing confirmed historical changes including the size extension do not impact safety or effectiveness.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →